Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264180 · ClinicalTrials.gov registry record · Phase 3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
A Phase 3 study of Advanced Melanoma, sponsored by Replimune.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06264180: Recruiting Phase 3 study of Advanced Melanoma, sponsored by Replimune.
NCT06264180 is a Phase 3 study of Advanced Melanoma that is actively recruiting participants, run by Replimune. The registered enrollment target is 400 participants, above the 153-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (161% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06264180, a Phase 3 study of Advanced Melanoma, is actively recruiting participants, sponsored by Replimune.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Primary Outcome
Time from the date of randomization to death due to any cause
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL Vusolimogene Oderparepvec
- BIOLOGICAL Nivolumab + Relatlimab
- DRUG Single-agent chemotherapy
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- The Angeles Clinic and Research Institute - Los Angeles
- USC Norris Comprehensive Cancer Center - Los Angeles
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
- UC Irvine Health, Chao Family Comprehensive Cancer Center - Orange
- Stanford Cancer Institute - Palo Alto
- Sutter Medical Group - Sacramento
- San Francisco Oncology Associates - San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion - Aurora
- The Melanoma and Skin Cancer Institute - Englewood
Florida
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern Memorial Hospital - Chicago
- Advocate Lutheran General Hospital - Park Ridge
Arizona
- Banner MD Anderson Cancer Center - Gilbert
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2034-08-31 |
| Phase | Phase 3 |
What NCT06264180 shows while recruiting
NCT06264180 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (161% higher).
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06264180 names 20 study sites across 9 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06264180 about?
NCT06264180 is a clinical study titled "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]". This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regim...
What is the current status of trial NCT06264180?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-07-11. Estimated completion is 2034-08-31.
What conditions does trial NCT06264180 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06264180?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Vusolimogene Oderparepvec (BIOLOGICAL), Nivolumab + Relatlimab (BIOLOGICAL), Single-agent chemotherapy (DRUG).
Who is sponsoring clinical trial NCT06264180?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06264180 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06264180's enrollment target sits among peer trials
400 4th of 21 higher than 18 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RECRUITING · Phase 3
-
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
RECRUITING · Phase 3
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
RECRUITING · Early Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI